2023 World Conference on Lung Cancer (Posters)-P1.21. Genetic Susceptibility to Immune Checkpoints Blockade Resistance

Pdf Summary

The study analyzed the role of genetic susceptibility in immune response and resistance to immune checkpoint blockade therapy in patients with non-small cell lung cancer (NSCLC). A cohort of 326 NSCLC patients who received this therapy were examined, with 60 patients chosen for exome sequencing analysis.<br /><br />The analysis revealed 26 germline variants associated with overall survival and progression-free survival, as well as 52 gene variants associated with response to immune checkpoint blockade therapy. These variants were mostly missense or stop gain/loss mutations.<br /><br />Several specific gene variants were identified as independent prognostic factors for overall survival, including IGFLR1c.565TC, ZNRF4c.488GA, and RREB1c.4315GA. Additionally, SLC17A3c.298GA, SAMM50c.329AG, and RREB1c.4315GA were identified as predictive factors for response at 6 months.<br /><br />The study emphasizes the importance of considering genetic susceptibility in predicting the success of immune checkpoint blockade therapy. By identifying specific germline variants associated with treatment outcomes, researchers aim to develop better biomarkers for personalized cancer treatment.<br /><br />Overall, the study suggests that analyzing germline variants through exome sequencing could be a valuable tool in identifying biomarkers of immune resistance in NSCLC patients undergoing immune checkpoint blockade therapy. Further research is needed to validate these findings and explore their potential applications in a clinical setting.<br /><br />The document contains survival data, statistical analyses, and demographic information. It also includes a Foster plot illustrating survival outcomes and a table presenting the analysis results. A Google Drive link is provided for additional related information.

Asset Subtitle

Jose Benítez

Meta Tag

Speaker Jose Benítez

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

genetic susceptibility

immune response

immune checkpoint blockade therapy

non-small cell lung cancer

NSCLC

exome sequencing analysis

germline variants

overall survival

progression-free survival

response to therapy